LetterLetter
Open Access

Vitamin D potentiates STING agonist-induced antitumor immunity in NSCLC

Ke Li, Guichao Liu, Wenhui Yuan, Xinhai Zhu and Peng Li
Cancer Biology & Medicine July 2026, 20260211; DOI: https://doi.org/10.20892/j.issn.2095-3941.2026.0211

References

  1. 1.↵
    2. Zhang D,
    3. Liu G,
    4. Ye J,
    5. Li K,
    6. Zhang G,
    7. Quan Q, et al.
    Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study. BMC Cancer. 2025; 25: 178.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Chen S,
    3. Wang Z,
    4. Sun B.
    Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC. Cancer Biol Med. 2025; 22: 191–6.
    OpenUrlFREE Full Text
  3. 3.↵
    2. Pauken KE,
    3. Alhalabi O,
    4. Goswami S,
    5. Sharma P.
    Neoadjuvant immune checkpoint therapy: enabling insights into fundamental human immunology and clinical benefit. Cancer Cell. 2025; 43: 623–40.
    OpenUrlPubMed
  4. 4.↵
    2. Ramanjulu JM,
    3. Pesiridis GS,
    4. Yang J,
    5. Concha N,
    6. Singhaus R,
    7. Zhang SY, et al.
    Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018; 564: 439–43.
    OpenUrlCrossRefPubMed
  5. 5.
    2. Pan BS,
    3. Perera SA,
    4. Piesvaux JA,
    5. Presland JP,
    6. Schroeder GK,
    7. Cumming JN, et al.
    An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020; 369: eaba6098.
  6. 6.↵
    2. Samson N,
    3. Ablasser A.
    The cGAS-STING pathway and cancer. Nat Cancer. 2022; 3: 1452–63.
    OpenUrlPubMed
  7. 7.↵
    2. Motedayen Aval L,
    3. Pease JE,
    4. Sharma R,
    5. Pinato DJ.
    Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J Clin Med. 2020; 9: 3323.
    OpenUrlPubMed
  8. 8.↵
    2. Lanng KRB,
    3. Lauridsen EL,
    4. Jakobsen MR.
    The balance of STING signaling orchestrates immunity in cancer. Nat Immunol. 2024; 25: 1144–57.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Raynor JL,
    3. Chi H.
    Nutrients: signal 4 in T cell immunity. J Exp Med. 2024; 221: e20221839.
  10. 10.
    2. Li P,
    3. Zhu X,
    4. Cao G,
    5. Wu R,
    6. Li K,
    7. Yuan W, et al.
    1α,25(OH)2D3 reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells. J Immunother Cancer. 2022; 10: e003477.
  11. 11.
    2. Aliazis K,
    3. Christofides A,
    4. Shah R,
    5. Yeo YY,
    6. Jiang S,
    7. Charest A, et al.
    The tumor microenvironment’s role in the response to immune checkpoint blockade. Nat Cancer. 2025; 6: 924–37.
    OpenUrlPubMed
  12. 12.
    2. Longo J,
    3. Watson MJ,
    4. Williams KS,
    5. Sheldon RD,
    6. Jones RG.
    Nutrient allocation fuels T cell-mediated immunity. Cell Metab. 2025; 37: 2311–22.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Ma S,
    3. Dahabieh MS,
    4. Mann TH,
    5. Zhao S,
    6. McDonald B,
    7. Song WS, et al.
    Nutrient-driven histone code determines exhausted CD8+ T cell fates. Science. 2025; 387: eadj3020.
  14. 14.↵
    2. Elkrief A,
    3. Méndez-Salazar EO,
    4. Maillou J,
    5. Vanderbilt CM,
    6. Gogia P,
    7. Desilets A, et al.
    Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. NPJ Precis Oncol. 2024; 8: 143.
    OpenUrlPubMed
  15. 15.↵
    2. Pinato DJ,
    3. Howlett S,
    4. Ottaviani D,
    5. Urus H,
    6. Patel A,
    7. Mineo T, et al.
    Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019; 5: 1774–8.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section